These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14744832)

  • 1. Tests for multivariate recurrent events in the presence of a terminal event.
    Chen BE; Cook RJ
    Biostatistics; 2004 Jan; 5(1):129-43. PubMed ID: 14744832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-inferiority trial design for recurrent events.
    Cook RJ; Lee KA; Li H
    Stat Med; 2007 Nov; 26(25):4563-77. PubMed ID: 17380542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
    BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
    Horváth Z
    Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
    Fitch MI; Maxwell C
    Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
    Freedman OC; Amir E; Clemons MJ
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust tests for treatment effects based on censored recurrent event data observed over multiple periods.
    Cook RJ; Wei W; Yi GY
    Biometrics; 2005 Sep; 61(3):692-701. PubMed ID: 16135020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of bisphosphonates in cancer patients.
    Wu S; Dahut WL; Gulley JL
    Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of morbidity in clinical studies with recurrent skeletal complications.
    Moecks J; Koch GG; Scott M; Budde M; Givens S; Koehler W; Knoessl M
    J Biopharm Stat; 2004 May; 14(2):415-37. PubMed ID: 15206537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.